Welcome to our dedicated page for Adverum Biotech news (Ticker: ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotech stock.
Adverum Biotechnologies, Inc. (ADVM) generated a stream of news as a clinical-stage gene therapy company focused on highly prevalent ocular diseases, particularly neovascular or wet age-related macular degeneration (wet AMD). Company releases consistently describe Adverum’s goal of establishing intravitreal gene therapy as a new standard of care, using durable, single-administration treatments to preserve sight and potentially prevent blindness.
News coverage for ADVM has centered on the development of its lead gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly ADVM-022). Updates have included milestones in the pivotal Phase 3 ARTEMIS trial for wet AMD, such as initiation, screening progress, and the completion of target enrollment of 284 patients, as reported in SEC filings and press releases. Additional articles have highlighted long-term follow-up data from earlier studies like OPTIC and LUNA, as well as scientific presentations on Ixo-vec biodistribution and aflibercept expression in the eye.
Investors following ADVM-related news can also see announcements about regulatory designations for Ixo-vec, including Fast Track and RMAT status from the U.S. FDA, PRIME designation from the European Medicines Agency, and the Innovation Passport in the UK. Corporate updates have covered financing activities, inducement equity grants under the 2017 Inducement Plan, and participation in ophthalmology conferences.
A major theme in later news is the strategic transaction with Eli Lilly and Company. Releases dated October and December 2025 detail Lilly’s tender offer to acquire all outstanding Adverum shares for cash plus a non-tradable contingent value right (CVR), and the subsequent expiration and completion of the tender offer with all conditions satisfied. This news page therefore serves both as a record of Adverum’s clinical and corporate developments and as an archive of announcements leading up to and including its acquisition by Lilly.
Adverum Biotechnologies (Nasdaq: ADVM) announced long-term findings from the OPTIC trial, showing the potential of ADVM-022 gene therapy for wet AMD. After a median follow-up of 88 weeks for the 2 x 1011 vg/eye dose, 60% of patients were injection-free for over a year. Aflibercept protein expression levels were maintained within therapeutic ranges. However, patient safety remains a priority following an unexpected adverse event in the INFINITY study. Ocular adverse events were primarily mild, with a significant reduction in anti-VEGF injection frequency reported.
The Sonic Fund II, L.P. owns approximately 6.8% of Adverum Biotechnologies (NASDAQ: ADVM) and criticized the Company following its announcement of a Suspected Unexpected Serious Adverse Reaction (SUSAR) in the INFINITY clinical trial for ADVM-022 gene therapy aimed at diabetic macular edema. Sonic claims this reflects a failure in the Company's development approach and loss of shareholder confidence, highlighted by a ~60% stock price drop. They urge immediate changes to the Board, proposing their independent nominees to restore trust and success in ADVM-022's development.
Adverum Biotechnologies (Nasdaq: ADVM) reported a Serious Adverse Reaction (SUSAR) of hypotony in a patient during its INFINITY clinical trial for ADVM-022, a gene therapy targeting diabetic macular edema. The incident occurred 30 weeks post-treatment with the high dose of ADVM-022. To ensure patient safety, Adverum will unmask the Phase 2 study and review data thoroughly. The INFINITY trial had completed patient dosing by December 2020 and included 36 participants to assess the efficacy of ADVM-022 versus aflibercept.
The Sonic Fund II, L.P. currently holds approximately 6.8% of Adverum Biotechnologies' outstanding common stock (NASDAQ: ADVM). Sonic has issued a supplemental presentation correcting recent misstatements by Adverum and has nominated three independent candidates—Jean Bennett, Jodi Cook, and Herbert Hughes—for election to the Board of Directors at the 2021 Annual Meeting. The presentation is titled “Adverum’s Myths: Correcting the Record” and is available for review online.
The Sonic Fund II, owning 6.8% of Adverum Biotechnologies (NASDAQ: ADVM), has nominated three independent candidates for the Board to enhance governance. The investor presentation criticizes Adverum's management of ADVM-022, its wet AMD treatment, citing poor scientific development and miscommunication with investors. Sonic argues that adding independent directors is essential to improve accountability and strategic oversight to restore stockholder confidence. The presentation encourages stockholders to vote for the independent nominees using the GREEN proxy card.
Adverum Biotechnologies (Nasdaq: ADVM) encourages stockholders to vote for its three independent director nominees at the Annual Meeting on May 12, 2021. The company claims that its gene therapy candidate, ADVM-022, is making significant clinical progress, with a potential Biologics License Application submission in 2024. Adverum has delivered strong stockholder returns, outperforming peers, and is refining its board composition to enhance commercial expertise. The company argues that rival Sonic's nominees would undermine board diversity and operational success.
Adverum Biotechnologies (Nasdaq: ADVM) is urging stockholders to vote for its three director nominees in the upcoming Annual Meeting on May 12, 2021. The company believes Sonic's nominees lack the necessary qualifications to advance its commercialization of ADVM-022, a gene therapy targeting vision-saving treatments. Adverum emphasizes that its board is well-qualified, having recently appointed seven new independent directors. The company is poised for significant progress, aiming for a Biologics License Application submission in 2024, supporting the vision-saving therapy for wet AMD and DME.
The Sonic Fund II, L.P. has filed a definitive proxy statement aiming to elect three independent director nominees to the Board of Adverum Biotechnologies (NASDAQ: ADVM) during the 2021 Annual Meeting, scheduled for May 12, 2021. Sonic, owning approximately 6.8% of ADVM's common stock, expresses concerns over Adverum's lack of governance and operational progress, which they believe has diminished stockholder value. They propose nominees with significant expertise in gene therapy and financial leadership, criticizing the current Board for failing to consider these candidates and for using questionable tactics that may disenfranchise stockholders.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) announced a webcast with key opinion leaders on May 2, 2021, at 7:00 AM PT. The event will feature data from the OPTIC clinical trial for ADVM-022, a gene therapy for wet age-related macular degeneration, and preclinical findings on ADVM-062 for blue cone monochromacy. Presentations will occur on May 3, 2021, during the ARVO 2021 Virtual Meeting. Additionally, on May 6, 2021, Adverum will report first-quarter 2021 financial results. More details can be found on Adverum's website.
Adverum Biotechnologies, Inc. (ADVM) has urged shareholders to vote for its nominated directors at the virtual Annual Meeting on May 12, 2021. The Board recommends the WHITE proxy card for Dawn Svoronos, Reed Tuckson, M.D., and Tom Woiwode, Ph.D., emphasizing their qualifications and independence. Adverum stated that a competing slate from activist shareholder Sonic poses risks to the company’s strategic direction and progress, particularly regarding the development of ADVM-022, a gene therapy targeting vision loss. The company aims to accelerate its commercialization and clinical trials as it prepares for FDA submission.
FAQ
What is the current stock price of Adverum Biotech (ADVM)?
What is the market cap of Adverum Biotech (ADVM)?
